Silence Therapeutics (SLN) Return on Equity (2024 - 2026)

Silence Therapeutics has disclosed Return on Equity across 3 years of filings, most recently posting 0.01% for Q1 2026.

• Return on Equity for Q1 2026 came in at 0.01%, down 1.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (down 1.0% YoY), and the FY2025 annual result was 0.01%, changed 0.0% from the prior year.
• Return on Equity came in at 0.01% for Q1 2026 at Silence Therapeutics, down from 0.01% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.0% in Q1 2024 to a low of 0.01% in Q1 2026.
• The 3-year median for Return on Equity is 0.01% (2025), against an average of 0.01%.
• Peak annual rise in Return on Equity reached 0 bps in 2025, while the deepest fall reached 1 bps in 2025.
• Silence Therapeutics' Return on Equity stood at 0.0% in 2024, then slumped by 278 bps to 0.01% in 2025, then fell by 4 bps to 0.01% in 2026.
• The last three Return on Equity figures came in at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.